Abstract：Objective: To investigate the clinical effect of transurethral holmium laser enucleation of the prostate (HoLEP) in treating patients with recurrent benign prostatic hyperplasia (BPH). Methods: Sixty patients who developed moderate to severe lower urinary tract obstruction symptoms after undergoing transurethral resection of the prostate (TURP) and were treated in the Urology Department of Chengde Central Hospital from September 2020 to September 2023 were selected as the study subjects. The patients were randomly divided into two groups according to a random number table: control group and observation group, with 30 patients in each group. The control group underwent TURP, while the observation group underwent HoLEP. The clinical effectiveness of the two groups was compared. Results: Before treatment, there were no significant differences in prostate function and recovery scores between the two groups (P>0.05). After treatment, both groups showed significant improvement (P<0.05), with the observation group showing significantly better results than the control group, with statistically significant differences (P<0.05). The incidence of postoperative complications in the observation group was lower than that in the control group (P<0.05). Additionally, clinical indicators such as operation time, hospital stay, blood loss, and bladder irrigation time in the observation group were better than those in the control group (P<0.05). Conclusion: In the surgical treatment of recurrent BPH, transurethral HoLEP not only enhances the effectiveness and safety of the procedure but also reduces the incidence of postoperative complications, making it worthy of clinical promotion.
[1] 向宸辉,王鹏桥,陈胜龙.钬激光剜除术治疗复发或残留前列腺增生的可行性分析[J].西南国防医药,2017,27(8):824-827. [2] 徐万海,王志超,赵丹凤,等.钬激光前列腺剜除术对复发性前列腺增生治疗的临床分析[J].中国激光医学杂志,2017,26(6):320-323. [3] Liu S,Garcia-Marques F,Zhang CA,et al.Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay[J].Sci Rep,2021,11(1):7612. [4] 北京医学会男科学分会.经尿道钬激光前列腺剜除术治疗良性前列腺增生专家共识[J].标记免疫分析与临床,2023,30(5):729-735. [5] 施量,杜凌云.不同手术时期对膀胱癌合并前列腺增生手术治疗对前列腺窝种植转移影响[J].贵州医药,2023,47(2):187-189. [6] Mokos I,El Saleh A,Kulis T,et al.Surgical treatment of high-risk prostatic carcinoma and oligometastatic disease[J].Acta Clin Croat,2019,58(2):21-23. [7] 熊斌,鲁伟.经尿道等离子剜除术与经尿道等离子电切术治疗前列腺增生的效果比较[J].国际泌尿系统杂志,2023,43(4):586-589. [8] Nakiri M,Ueda K,Ogasawara N,et al.Tri-modality therapy with i-125 brachytherapy,external beam radiation therapy,and short-term hormone therapy for high-risk prostate cancer after holmium laser enucleation of the prostate[J].IJU Case Rep,2022,5(4):223-226. [9] 苏斌杰,陈刚.经尿道前列腺1470nm激光汽化术治疗良性前列腺增生的临床疗效[J].医学临床研究,2023,40(7):984-986,990. [10] 赵国瑛.钬激光前列腺剜除术与经尿道等离子前列腺 剜除电切术治疗良性前列腺增生患者的临床效果分 析[J].四川生理科学杂志,2021,43(2):204-206. [11] Tolani MA,Suleiman A,Awaisu M,et al.Acute urinary tract infection in patients with underlying benign prostatic hyperplasia and prostate cancer[J].Pan Afr Med,2020(36):169. [12] 陈昊,董自强.经尿道前列腺双极等离子电切术与经尿 道前列腺钬激光剜除术治疗大体积良性前列腺增生 症的临床分析[J].广州医药,2022,53(1):133-136. [13] Medina-Polo J,Teigell Tobar J,Romero-Otero J,et al.Manejo de la hiperplasia benigna de prostata durante la pandemia COVID-19 [Benign prostatic hyperplasia management during COVID-19 pandemia.][J].Arch Esp Urol,2020,73(5):405-412. [14] Vandergrift LA,Decelle EA,Kurth J,et al.Metabolomic prediction of human prostate cancer aggressiveness:magnetic resonance spectroscopy of histologically benign tissue[J].Sci Rep,2018,8(1):4997. [15] Guilhen M,Hennequin C,Ouzaid I,et al.Urinary function and quality of life after radiotherapy for prostate cancer in patients with prior history of surgical treatment for benign prostatic hyperplasia[J].Radiat Oncol,2018,13(1):209. [16] 刘继普,钟煜韡,郑永宏,等.经尿道前列腺钬激光剜除术与经尿道前列腺电切术治疗良性前列腺增生的临 床对比[J].中外医疗,2021,40(21):85-88.
2024, Vol. 30 
冀公网安备13080202000677号